A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?

Basic and Clinical Pharmacology and Toxicology

Volumn 121, Issue 4, 2017, Pages 303-308

  Pea, Federico ^a,b   Cojutti, Pier Giorgio ^a,b   Baraldo, Massimo ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LINEZOLID; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GRAM POSITIVE INFECTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL WARD; TREATMENT DURATION; BLOOD; HOSPITAL PATIENT; ITALY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROCEDURES; STATISTICAL MODEL; TIME FACTOR;

AGED; ANTI-BACTERIAL AGENTS; DRUG MONITORING; FEMALE; HUMANS; INPATIENTS; ITALY; LINEZOLID; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85021129233     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12797     Document Type: Article

References (32)

1. Reeves D, Lovering A, Thomson A. Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother 2016;71:3330–2.
2. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012;73:27–36.
3. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001;61:525–51.
4. Morata L, Tornero E, Martinez-Pastor JC, Garcia-Ramiro S, Mensa J, Soriano A. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother 2014;69(Suppl 1):i47–52.
5. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2016;15:41.
6. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508–18.
7. Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther 2016;14:901–15.
8. Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 2014;58:2334–43.
9. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010;54:4605–10.
10. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012;67:2034–42.
11. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006;42:434–5.
12. Pea F, Cadeo B, Cojutti PG, Pecori D, Bassetti M. Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. Ther Drug Monit 2014;36:687–9.
13. Cojutti P, Crapis M, Bassetti M, Hope W, Pea F. Linezolid underexposure in a patient co-treated with venlafaxine. Eur J Clin Pharmacol 2015;71:1285–6.
14. Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F. Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 2015;70:198–206.
15. Morata L, Cuesta M, Rojas JF, Rodriguez S, Brunet M, Casals G et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother 2013;57:1913–7.
16. Dong HY, Xie J, Chen LH, Wang TT, Zhao YR, Dong YL. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis 2014;33:1029–35.
17. Zoller M, Maier B, Hornuss C, Neugebauer C, Dobbeler G, Nagel D et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 2014;18:R148.
18. Topper C, Steinbach CL, Dorn C, Kratzer A, Wicha SG, Schleibinger M et al. Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions. Ther Drug Monit 2016;38:573–8.
19. Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM et al. Predictors of inadequate linezolid concentrations after standard dosing in critically Ill patients. Antimicrob Agents Chemother 2016;60:5254–61.
20. Pea F, Cojutti P, Dose L, Baraldo M. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol 2016;81:341–8.
21. Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine 2015;2:1627–33.
22. Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents 2016;48:728–31.
23. Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS et al. Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis? Eur Respir J 2016;47:1288–90.
24. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013;57:1144–9.
25. Pea F, Dose L, Cojutti P, Baraldo M, Fontana F, Favaretti C et al. Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring. Basic Clin Pharmacol Toxicol 2014;115:432–7.
26. Morata L, De la Calle C, Gomez-Cerquera JM, Manzanedo L, Casals G, Brunet M et al. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother 2016;17:1183–7.
27. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003;47:3789–94.
28. Egle H, Trittler R, Kummerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005;77:451–3.
29. Ashizawa N, Tsuji Y, Kawago K, Higashi Y, Tashiro M, Nogami M et al. Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother 2016;22:331–4.
30. Hoyo I, Martinez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis 2012;44:548–50.
31. Pea F, Cojutti P, Pagotto A, Cristini F, Furlanut M, Viale P. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother 2012;56:3438–40.
32. Morata L, Senneville E, Bernard L, Nguyen S, Buzele R, Druon J et al. A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther 2014;3:235–43.